Category: genomics

Genomics and Precision Medicine: How Can Emerging Technologies Address Population Health Disparities? Join the Conversation.

different people standing on DNA in front of a world map

Advances in genome sequencing, other “omic” technologies, and big data promise a new era of personalized medicine. However, there is an ongoing discussion how these new technologies can be used to understand and address existing population health disparities. On October 11, 2017, the Precision Medicine and Population Health Interest Group in the Division of Cancer Read More >

Posted on by Wylie Burke, Professor Emeritus and former Chair, Department of Bioethics and Humanities, University of Washington, Charles Rotimi, Director, Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes for Health, Debbie Winn, Division of Cancer Control and Population Sciences, National Cancer Institute, Vence Bonham and Michael Hahn, National Human Genome Research Institute, National Institutes for Health, Muin J, Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags

Integrating Pharmacogenomics in Practice: One GIFT at a Time or a Package Deal?

a present opened with DNA capsuls spilling out of them

Testing for genetic variants related to warfarin metabolism has been the poster child for pharmacogenomics in clinical practice for over a decade. A recent publication of the Genetic Informatics Trial (GIFT) provides additional evidence for the clinical benefits of incorporating pharmacogenomics testing into the management of warfarin initiation. In this multicenter study of older individuals Read More >

Posted on by W. Gregory Feero M.D., Ph.D. Faculty, Maine-Dartmouth Family Medicine Residency Program, Augusta, Maine and Muin J. Khoury, MD, PhD, Office of Public Health Genomics, Centers for Disease Control and PreventionTags , ,

Trends and Factors Affecting Utilization of BRCA Testing in the United States: The Need for Improved Surveillance

hands holding a pink ribbon with the US map in the background

This blog post is a summary of two recent CDC papers on the trends in utilization of BRCA testing in the United States, and metropolitan-nonmetropolitan areas differences in testing. Women with pathogenic BRCA mutations have an estimated 45–65% risk of breast cancer and a 17–39% risk of ovarian cancer by age 70, as compared with Read More >

Posted on by Katherine Kolor, Zhuo Chen, and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and PreventionTags

Integrating genomics into population-based cancer surveillance in the era of precision medicine

individuals all over a map of the US with DNA and a magnifiying glass on one person

Population-based cancer surveillance provides a quantitative measurement of cancer occurrence in the United States and globally. Core activities of surveillance include measuring cancer incidence and characterizing each cancer with regard to histopathology, stage, and treatment in the context of survival. Cancer surveillance has been crucial in informing policy and practice, as well as clinical and Read More >

Posted on by Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia and Lynne Penberthy, Division of Cancer Control and Population Sciences, National Cancer InstituteTags ,

A New Public Health Assessment of the Disease Burden of Hereditary Hemochromatosis: How Clinically Actionable is C282Y Homozygosity?

blood cells

This blog post is based on a recent paper by Grosse, Gurrin, Bertalli, and Allen in Genetics in Medicine. Hereditary hemochromatosis (HH) attributable to mutations in the HFE gene is the most common autosomal recessive disorder among adults of northern European origin. It occurs in 1 in 300 non-Hispanic whites in the United States. Approximately Read More >

Posted on by Scott D. Grosse, Guest blogger, National Center on Birth Defects and Developmental Disabilities and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and PreventionTags , ,

Accelerating Evidence Generation to Fulfill the Promise of Genomic Medicine

a long road with a lighting speed trail, a computer monitor with electronic health record displayed and DNA in the sky

This blog post is a summary of a recently published paper in Genetics in Medicine. Genomic tests should demonstrate analytical and clinical validity and clinical utility prior to wider adoption in clinical practice. However, clinical utility remains elusive for many such tests. A recent collaborative review of systematic reviews that compared the analytic and clinical Read More >

Posted on by Christine Y Lu, guest blogger, Harvard Medical School, Boston, Mass and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention.Tags ,

Cascade Screening for Familial Hypercholesterolemia in the United States: Public Health Impact and Challenges

a predigree with hearts on a US map

This post is a summary of our recently published paper in JAMA and outlines the public health impact and challenges for cascade screening for Familial Hypercholesterolemia (FH) in the United States.   What is the public health impact of cascade screening for FH? FH is a dominantly-inherited genetic disorder affecting about 1 in 250 people and Read More >

Posted on by Joshua W. Knowles, guest blogger, Division of Cardiovascular Medicine and Cardiovascular Institute Stanford University, California; Daniel J. Rader, guest blogger, Department of Human Genetics, University of Pennsylvania, Philadelphia, PA; and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control & Prevention, Atlanta, GATags ,

Is pharmacogenetic-guided treatment cost-effective? No one size fits all!

a pill filled with DNA and dollar signs around

A recently published article by M. Verbelen and colleagues in The Pharmacogenomics Journal is called, “Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?” As Betteridge’s law of headlines states, any headline that ends in a question mark can be answered by the word No. Regrettably, although that article presents useful information, it ends up by Read More >

Posted on by Scott D. Grosse, National Center on Birth Defects and Developmental Disabilities and W. Dave Dotson, Office of Public Health Genomics, Centers for Disease Control and Prevention2 CommentsTags

Integrating Genomics into Public Health Surveillance: Ushering in a New Era of Precision Public Health

a crowd of people standing on sequincing and DNA and data graphs

Public health surveillance has been defined as “the ongoing systematic collection, analysis, and interpretation of data, closely integrated with the dissemination of these data to the public health practitioners, clinicians, and policy makers responsible for preventing and controlling disease and injury.” Surveillance provides an essential scientific foundation for both clinical and public health practice. In Read More >

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and PreventionTags

Whole Genome Sequencing for All? The Quest for Evidence Continues

a clinician holdig a stethoscope with DNA on the side

In 1999, Dr. Francis Collins predicted what the practice of genomic medicine in primary care may look like in 2010. He used a hypothetical patient named John, a 23-year-old man with high serum cholesterol. Based on his father’s history of early onset heart disease, John underwent a battery of genetic tests. He was found to Read More >

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention3 CommentsTags